{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:49:54Z","timestamp":1787168994084,"version":"build-2736575974"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.phrs.2015.03.009","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T16:05:26Z","timestamp":1428249926000},"page":"111-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Lipids, blood pressure and kidney update 2014"],"prefix":"10.1016","volume":"95-96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Serban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahabkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Voroneanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.03.009_bib0940","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11255-014-0657-6","article-title":"Lipid, blood pressure and kidney update 2013","volume":"46","author":"Banach","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib0945","article-title":"Contrasting cholesterol management guidelines for adults with CKD","author":"Colantonio","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib0950","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5114\/aoms.2014.43738","article-title":"Nicotinic acid\/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia","volume":"10","author":"Kei","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib0955","doi-asserted-by":"crossref","first-page":"585","DOI":"10.5114\/aoms.2013.37275","article-title":"Statin treatment in the elderly: how much do we know?","volume":"9","author":"Rizzo","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib0960","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib0965","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia. Part 1 \u2013 Executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib0970","first-page":"15","article-title":"Use of statins in patients with liver disease","volume":"60","author":"Kalaitzakis","year":"2014","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"10.1016\/j.phrs.2015.03.009_bib0975","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.2174\/1381612811319270014","article-title":"Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance","volume":"19","author":"Banach","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2015.03.009_bib0980","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.2174\/13816128113196660678","article-title":"Statins and new-onset diabetes","volume":"20","author":"Barylski","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2015.03.009_bib0985","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5114\/aoms.2013.35424","article-title":"Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study","volume":"9","author":"Athyros","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib0990","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5114\/aoms.2013.35327","article-title":"Persistence with statin therapy in Hungary","volume":"9","author":"Kiss","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib0995","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2014.06.007","article-title":"Statins in neurological disorders: an overview and update","volume":"88","author":"Malfitano","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.03.009_bib1000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/17512433.2014.857601","article-title":"Statin intolerance: more questions than answers","volume":"7","author":"Guyton","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 acc\/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.03.009_bib1010","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2014.02.033","article-title":"Statin intolerance","volume":"113","author":"Ahmad","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.5114\/aoms.2011.26620","article-title":"Lipids, blood pressure, kidney \u2013 what was new in 2011?","volume":"7","author":"Barylski","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1020","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the meteor trial","volume":"297","author":"Crouse","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1053\/euhj.1998.1350","article-title":"MRC\/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience","volume":"20","year":"1999","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1074248414539562","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibitors an emerging lipid-lowering therapy?","volume":"20","author":"Dragan","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.03.009_bib1035","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-pcsk9 antibody effectively lowers cholesterol in patients with statin intolerance: the gauss-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to pcsk9, in statin-intolerant patients: design and rationale of odyssey alternative, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance \u2013 an attempt at a unified definition. Position paper from an international lipid expert panel","author":"Banach","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1050","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European atherosclerosis society consensus panel statement on assessment, aetiology and management","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1055","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacl.2014.05.005","article-title":"Hypothyroidism as a risk factor for statin intolerance","volume":"8","author":"Robison","year":"2014","journal-title":"J. Clin. Lipidol."},{"issue":"11","key":"10.1016\/j.phrs.2015.03.009_bib1065","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/gim.2014.41","article-title":"Genetic factors affecting statin concentrations and subsequent myopathy: a hugenet systematic review","volume":"16","author":"Canestaro","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1070","doi-asserted-by":"crossref","first-page":"A145","DOI":"10.1161\/res.115.suppl_1.145","article-title":"Mitophagy protects against statin-induced cell death in muscle cells","volume":"115","author":"Andres","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2015.03.009_bib1075","first-page":"24","article-title":"Effects of coenzyme q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015"},{"key":"10.1016\/j.phrs.2015.03.009_bib1080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","article-title":"Analysis of vitamin d levels in patients with and without statin-associated myalgia\u2014a systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Michalska-Kasiczak","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1085","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1097\/HJH.0000000000000254","volume":"32","author":"Zanchetti","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2015.03.009_bib1090","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5114\/aoms.2013.33357","article-title":"The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-\u03b3 activating capacity on plasma 8-isoprostane prostaglandin f2a levels","volume":"9","author":"Rizos","year":"2013","journal-title":"Arch. Med. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2015.03.009_bib1095","doi-asserted-by":"crossref","first-page":"622","DOI":"10.5114\/aoms.2013.36905","article-title":"Effect of statins on platelet function in patients with hyperlipidemia","volume":"9","author":"Sikora","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5114\/aoms.2013.33357","article-title":"The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-\u03b3 activating capacity on plasma 8-isoprostane prostaglandin f2a levels","volume":"9","author":"Rizos","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.phrs.2014.06.011","article-title":"Statins in chronic kidney disease and kidney transplantation","volume":"88","author":"Kassimatis","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2015.03.009_bib1110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/clpt.2014.85","article-title":"An overview of the new frontiers in the treatment of atherogenic dyslipidemias","volume":"96","author":"Rached","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.03.009_bib1115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the jupiter trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.03.009_bib1120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2013.04.001","article-title":"The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin\/kexin 9 inhibitors","volume":"73","author":"Shen","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.03.009_bib1125","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.2174\/13816128113199990303","article-title":"Pcsk9 inhibition \u2013 a novel mechanism to treat lipid disorders?","volume":"19","author":"Banach","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2015.03.009_bib1130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2014.01.001","article-title":"Management of familial hypercholesterolemia in children and adolescents. Position paper of the polish lipid expert forum","volume":"8","author":"My\u015bliwiec","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1135","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1140","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-pcsk9 monotherapy for hypercholesterolemia: the mendel-2 randomized, controlled phase iii clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1145","article-title":"Pcsk9 inhibition with evolocumab (amg 145) in heterozygous familial hypercholesterolaemia (rutherford-2): a randomised, double-blind, placebo-controlled trial","author":"Raal","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2015.03.009_bib1150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the odyssey FH studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2015.03.009_bib1155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2261-14-121","article-title":"Efficacy and safety of alirocumab, a fully human pcsk9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the odyssey combo i and ii trials","volume":"14","author":"Colhoun","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"issue":"9965","key":"10.1016\/j.phrs.2015.03.009_bib1160","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of pcsk9 with evolocumab in homozygous familial hypercholesterolaemia (tesla part b): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2015.03.009_bib1165","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"The task force for the management of dyslipidaemias of the European society of cardiology (esc) and the European atherosclerosis society (eas). Esc\/eas guidelines for the management of dyslipidaemias","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1170","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-c lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.phrs.2015.03.009_bib1175","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of odyssey alternative, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1180","series-title":"ESC Hot Line Session Barcelona","article-title":"Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the odyssey long term study in 2,341 patients","author":"Robinson","year":"2014"},{"key":"10.1016\/j.phrs.2015.03.009_bib1185","series-title":"Improve-it Trial: A Comparison of Ezetimibe\/Simvastatin Versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes","author":"Cannon","year":"2014"},{"key":"10.1016\/j.phrs.2015.03.009_bib1190","first-page":"1","article-title":"Lipoprotein (a) as a therapeutic target in cardiovascular disease","author":"Koschinsky","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.phrs.2015.03.009_bib1195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/joim.12207","article-title":"Genetic determination of lipoprotein(a) and its association with cardiovascular disease: convenient does not always mean better","volume":"276","author":"Kronenberg","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1200","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOL.0000000000000131","article-title":"What is the ultimate test that lowering lipoprotein (a) is beneficial for cardiovascular disease and aortic stenosis?","volume":"25","author":"Hung","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1205","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein (a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2015.03.009_bib1215","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.114.303462","article-title":"A common lpa null allele associates with lower lipoprotein (a) levels and coronary artery disease risk","volume":"34","author":"Kyriakou","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1220","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2015.03.009_bib1225","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein (a) with PCSK9 monoclonal antibody evolocumab (amg 145): a pooled analysis of more than 1300 patients in 4 phase ii trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1230","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein (a) concentrations (a pooled analysis of 150mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1235","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.atherosclerosis.2014.10.099","article-title":"Etc-1002: a future option for lipid disorders?","volume":"237","author":"Nikolic","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2015.03.009_bib1240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/clpt.2014.85","article-title":"An overview of the new frontiers in the treatment of atherogenic dyslipidemias","volume":"96","author":"Rached","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.03.009_bib1245","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5114\/aoms.2014.42587","article-title":"Dietary and nutraceutical approach to type 2 diabetes","volume":"10","author":"Derosa","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-014-0450-0","article-title":"N-3 fatty acids for prevention of cardiovascular disease","volume":"16","author":"Khawaja","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.phrs.2015.03.009_bib1255","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the epanova for lowering very high triglycerides (evolve) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacl.2014.03.003","article-title":"Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia","author":"Jacobson","year":"2014","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1265","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.clinthera.2013.07.420","article-title":"A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the esprit trial)","volume":"35","author":"Maki","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2015.03.009_bib1270","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJMp1313866","article-title":"Assessing the clinical benefits of lipid-disorder drugs","volume":"370","author":"Hiatt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1275","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.2174\/1381612811319170020","article-title":"The role of fibrate treatment in dyslipidemia: an overview","volume":"19","author":"Katsiki","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2015.03.009_bib1280","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 acc\/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1285","doi-asserted-by":"crossref","first-page":"g4356","DOI":"10.1136\/bmj.g4356","article-title":"Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated nice guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"Br. Med. J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1290","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.2174\/13816128113199990324","article-title":"Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?","volume":"19","author":"Rizzo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2015.03.009_bib1295","doi-asserted-by":"crossref","first-page":"788","DOI":"10.5114\/aoms.2013.38671","article-title":"Differences in metabolic parameters and cardiovascular risk between American diabetes association and world health organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study","volume":"9","author":"Filippatos","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1300","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.beem.2013.11.001","article-title":"Emerging therapies for raising high-density lipoprotein cholesterol (hdl-c) and augmenting HDL particle functionality","volume":"28","author":"Barylski","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.03.009_bib1305","first-page":"cvu140","article-title":"Micrornas and HDL life cycle","author":"Canfr\u00e1n-Duque","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2015.03.009_bib1310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.phrs.2013.06.005","article-title":"Micrornas as pharmacological targets in diabetes","volume":"75","author":"Mao","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.03.009_bib1315","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2013.02.005","article-title":"From evolution to revolution: mirnas as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport","volume":"75","author":"D\u00e1valos","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.03.009_bib1320","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"Micrornas are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1325","doi-asserted-by":"crossref","first-page":"e003376","DOI":"10.1161\/JAHA.112.003376","article-title":"Microrna-33 deficiency reduces the progression of atherosclerotic plaque in apoe\u2212\/\u2212 mice","volume":"1","author":"Horie","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1330","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of mir-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121","author":"Rayner","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2015.03.009_bib1335","doi-asserted-by":"crossref","first-page":"870","DOI":"10.5114\/aoms.2014.46208","article-title":"Carotid intima media thickness and low high-density lipoprotein (HDL) in south Asian immigrants: could dysfunctional HDL be the missing link?","volume":"10","author":"Dodani","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1340","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.5114\/aoms.2014.41348","article-title":"Pon1 status evaluation in patients with chronic arterial occlusion of lower limbs due to atherosclerosis obliterans","volume":"10","author":"Kasprzak","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1345","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5114\/aoms.2013.33176","article-title":"Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase a2 and carboxyl ester lipase lipases in atherosclerotic plaque formation","volume":"9","author":"Burchardt","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1350","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.beem.2013.11.002","article-title":"Should low high-density lipoprotein cholesterol (hdl-c) be treated?","volume":"28","author":"Toth","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.03.009_bib1355","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.2174\/0929867321666140303153829","article-title":"Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?","volume":"21","author":"Dragan","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2015.03.009_bib1360","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5114\/aoms.2014.42586","article-title":"Hla-dr expression, cytokines and bioactive lipids in sepsis","volume":"10","author":"Das","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1365","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/clp.13.83","article-title":"Dysfunctional HDL: the journey from savior to slayer","volume":"9","author":"Serban","year":"2014","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1370","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nm.3459","article-title":"An abundant dysfunctional apolipoprotein a1 in human atheroma","volume":"20","author":"Huang","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1375","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1380","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.atherosclerosis.2014.05.496","article-title":"Investigating dysfunctional-HDL in selected groups of patients at high risk of cardiovascular events (DYS-HDL study) \u2013 protocol and organization","volume":"235","author":"Banach","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2015.03.009_bib1385","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8)","volume":"311","author":"James","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1390","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.5114\/aoms.2014.47818","article-title":"Commentary on recent guidelines for treating hypertension","volume":"10","author":"Aronow","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1395","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/M13-2981","article-title":"Evidence supporting a systolic blood pressure goal of less than 150mm hg in patients aged 60 years or older: the minority view","volume":"160","author":"Wright","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1400","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","volume":"57","author":"Aronow","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1405","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5114\/aoms.2013.34419","article-title":"Health-related behaviours and hypertension prevention in poland. An environmental study","volume":"9","author":"Krzysztoszek","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1410","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jama.294.4.466","article-title":"Hypertension in adults across the age spectrum: current outcomes and control in the community","volume":"294","author":"Lloyd-Jones","year":"2005","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1415","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8)","volume":"311","author":"James","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1420","doi-asserted-by":"crossref","first-page":"830","DOI":"10.5114\/aoms.2013.34723","article-title":"Aliskiren-an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension","volume":"10","author":"Zaporowska-Stachowiak","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1425","first-page":"338","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","author":"Law","year":"2009","journal-title":"Br. Med. J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1430","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1435","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1440","doi-asserted-by":"crossref","first-page":"e7473","DOI":"10.1136\/bmj.e7473","article-title":"Resistant hypertension","volume":"345","author":"Myat","year":"2012","journal-title":"Br. Med. J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1445","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2015.03.009_bib1450","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jacc.2014.05.044","article-title":"2014 eighth joint national committee panel recommendation for blood pressure targets revisited: results from the invest study","volume":"64","author":"Bangalore","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1455","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","volume":"57","author":"Aronow","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1460","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jama.2014.2531","article-title":"Proportion of us adults potentially affected by the 2014 hypertension guideline","volume":"311","author":"Navar-Boggan","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1465","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jacc.2014.06.014","article-title":"2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations","volume":"64","author":"Krakoff","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1470","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijcard.2014.07.067","article-title":"Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication","volume":"176","author":"Banach","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1475","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1517\/14656566.2011.579106","article-title":"What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?","volume":"12","author":"Banach","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2015.03.009_bib1480","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s11906-012-0314-3","article-title":"Blood pressure J-curve: current concepts","volume":"14","author":"Banach","year":"2012","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.phrs.2015.03.009_bib1485","article-title":"What is targeted diastolic blood pressure in elderly patients? The results from the reasons for geographic and racial differences in stroke (regards) cohort study","volume":"35","author":"Banach","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1490","article-title":"Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults without antihypertensive medication","volume":"35","author":"Banach","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1495","article-title":"The effect of hypertension therapy in older adults. The results of a meta-analysis of 11 randomized control trials with 40325 patients","volume":"35","author":"Ostrowski","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1500","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community","volume":"16","author":"Weber","year":"2014","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.phrs.2015.03.009_bib1505","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5114\/aoms.2013.34534","article-title":"Echocardiographic indices of left ventricular hypertrophy and diastolic function in hypertensive patients with preserved lvef classified as dippers and non-dippers","volume":"20","author":"Mo\u017cd\u017can","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1510","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2007.01.119","article-title":"Secondary hypertension: current diagnosis and treatment","volume":"124","author":"Chiong","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1515","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/CIRCULATIONAHA.107.183885","volume":"115","author":"Rosendorff","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.03.009_bib1520","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.2010.884","article-title":"Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease","volume":"304","author":"Cooper-DeHoff","year":"2010","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1525","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1530","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/CIRCULATIONAHA.110.008870","article-title":"Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the ongoing Telmisartan alone and in combination with ramipril global endpoint trial (ontarget)","volume":"124","author":"Mancia","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.03.009_bib1535","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","article-title":"Safety and efficacy of low blood pressures among patients with diabetes subgroup analyses from the ontarget (ongoing Telmisartan alone and in combination with ramipril global endpoint trial)","volume":"59","author":"Redon","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1540","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1545","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20142013","volume":"36","author":"Association","year":"2013","journal-title":"Diab. Care"},{"key":"10.1016\/j.phrs.2015.03.009_bib1550","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-154-8-201104190-00335","article-title":"Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier","volume":"154","author":"Upadhyay","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1555","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1560","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/01.HYP.29.2.641","article-title":"Achievement and safety of a low blood pressure goal in chronic renal disease the modification of diet in renal disease study group","volume":"29","author":"Lazarus","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2015.03.009_bib1565","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (rein-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2015.03.009_bib1570","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/jhh.2012.3","article-title":"Hypertension therapy in the older adults\u2014do we know the answers to all the questions & quest; the status after publication of the accf\/aha 2011 expert consensus document on hypertension in the elderly","volume":"26","author":"Banach","year":"2012","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2015.03.009_bib1575","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2011.615902","article-title":"Ten most important things to learn from the accf\/aha 2011 expert consensus document on hypertension in the elderly","volume":"21","author":"Aronow","year":"2012","journal-title":"Blood Press."},{"key":"10.1016\/j.phrs.2015.03.009_bib1580","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/kisup.2012.53","article-title":"Chapter 3: blood pressure management in CKD ND patients without diabetes mellitus","volume":"2","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.phrs.2015.03.009_bib1585","first-page":"363","article-title":"Chapter 4: blood pressure management in CKD ND patients with diabetes mellitus","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.phrs.2015.03.009_bib1590","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","article-title":"Revascularization versus medical therapy for renal-artery stenosis","volume":"361","author":"Buller","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1595","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-150-12-200906160-00119","article-title":"Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function randomized trial","volume":"150","author":"Bax","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1600","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1310753","article-title":"Stenting and medical therapy for atherosclerotic renal-artery stenosis","volume":"370","author":"Cooper","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1605","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.110.163014","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension durability of blood pressure reduction out to 24 months","volume":"57","author":"Investigators","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2015.03.009_bib1610","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Symplicity htn-2 investigators renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): a randomised controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2015.03.009_bib1615","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.4244\/EIJV9SRA11","article-title":"Updated ESH position paper on interventional therapy of resistant hypertension","volume":"9","author":"Schmieder","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.phrs.2015.03.009_bib1620","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2015.03.009_bib1625","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2014.05.012","article-title":"Impact of renal denervation on 24-hour ambulatory blood pressure: results from symplicity htn-3","volume":"64","author":"Bakris","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1630","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jacc.2014.07.937","article-title":"Innervation patterns may limit response to endovascular renal denervation","volume":"64","author":"Tzafriri","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1635","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2014.03.001","article-title":"Reflections on renal denervation","volume":"63","author":"DeMaria","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1640","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2012080800","article-title":"Temporal changes in incidence of dialysis-requiring aki","volume":"24","author":"Hsu","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1645","first-page":"3","article-title":"The impact of acute kidney injury on the long-term risk of stroke","author":"Wu","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.phrs.2015.03.009_bib1650","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/j.ajkd.2014.08.024","article-title":"Hospital-acquired acute kidney injury and hospital readmission: a cohort study","volume":"65","author":"Koulouridis","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2015.03.009_bib1655","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ejcts.2009.01.024","article-title":"The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass","volume":"35","author":"Adluri","year":"2009","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"21","key":"10.1016\/j.phrs.2015.03.009_bib1660","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1001\/jama.2014.13573","article-title":"Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery a randomized clinical trial","volume":"312","author":"Landoni","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1665","first-page":"545","article-title":"Beneficial effect of aspirin on renal function in patients with renal insufficiency postcardiac surgery","volume":"45","author":"Gerrah","year":"2004","journal-title":"J. Cardiovasc. Surg."},{"key":"10.1016\/j.phrs.2015.03.009_bib1670","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1213\/01.ANE.0000117146.46373.51","article-title":"The effect of epidural clonidine on perioperative cytokine response, postoperative pain, and bowel function in patients undergoing colorectal surgery","volume":"99","author":"Wu","year":"2004","journal-title":"Anesth. Analg."},{"issue":"21","key":"10.1016\/j.phrs.2015.03.009_bib1675","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/jama.2014.15284","article-title":"Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial","volume":"312","author":"Garg","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1680","doi-asserted-by":"crossref","first-page":"c168","DOI":"10.1159\/000312881","article-title":"Is anemia at hospital admission associated with in-hospital acute kidney injury occurrence?","volume":"115","author":"Shema-Didi","year":"2010","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.phrs.2015.03.009_bib1685","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/rheumatology\/ken466","article-title":"Statins inhibit c-reactive protein-induced chemokine secretion, icam-1 upregulation and chemotaxis in adherent human monocytes","volume":"48","author":"Montecucco","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2015.03.009_bib1690","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.joca.2008.06.012","article-title":"Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation","volume":"17","author":"Akasaki","year":"2009","journal-title":"Osteoarthr. Cartil."},{"issue":"24","key":"10.1016\/j.phrs.2015.03.009_bib1695","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1700","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1503\/cmaj.130363","article-title":"Canadian society of nephrology 2014 clinical practice guideline for timing the initiation of chronic dialysis","volume":"186","author":"Nesrallah","year":"2014","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.phrs.2015.03.009_bib1705","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1710","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.phrs.2014.02.007","article-title":"Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD)","volume":"81","author":"Impellizzeri","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.phrs.2015.03.009_bib1715","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diab. Endocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2015.03.009_bib1720","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving raas inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2015.03.009_bib1725","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2015.03.009_bib1730","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1056\/NEJMe1414112","article-title":"A new era for the treatment of hyperkalemia?","volume":"372","author":"Ingelfinger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1735","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMe1004992","article-title":"Rituximab in anca-associated disease","volume":"363","author":"Falk","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1740","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in anca-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1745","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in anca-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1750","doi-asserted-by":"crossref","first-page":"G581","DOI":"10.1152\/ajpgi.90311.2008","article-title":"Role of muts homolog 2 (msh2) in intestinal myofibroblast proliferation during Crohn's disease stricture formation","volume":"295","author":"Floer","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2015.03.009_bib1755","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2014020173","article-title":"Subclinical atherosclerosis measures for cardiovascular prediction in CKD","volume":"26","author":"Matsushita","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1760","first-page":"1083","article-title":"Bone protective effect of simvastatin in experimental arthritis","volume":"35","author":"Funk","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1765","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","article-title":"Hypertension in autosomal dominant polycystic kidney disease","volume":"17","author":"Chapman","year":"2010","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.phrs.2015.03.009_bib1770","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study","volume":"13","author":"Schrier","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1775","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1780","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.03.009_bib1785","first-page":"1442","article-title":"Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease","volume":"174","author":"Kovesdy","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2015.03.009_bib1790","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","article-title":"A randomized trial of dietary sodium restriction in CKD","volume":"24","author":"McMahon","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1795","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.113.02793","article-title":"Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function","volume":"63","author":"Cirillo","year":"2014","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2015.03.009_bib1800","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ki.2013.336","article-title":"Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease","volume":"85","author":"Hung","year":"2014","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.phrs.2015.03.009_bib1805","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.ajkd.2014.01.420","article-title":"Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial","volume":"64","author":"Onofriescu","year":"2014","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.phrs.2015.03.009_bib1810","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1681\/ASN.2012100990","article-title":"Pulmonary congestion predicts cardiac events and mortality in ESRD","volume":"24","author":"Zoccali","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1815","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/ndt\/gft260","article-title":"Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters","volume":"28","author":"Siriopol","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2015.03.009_bib1820","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/ndt\/gft425","article-title":"Lung congestion as a hidden threat in end-stage kidney disease: a call to action","volume":"28","author":"Zoccali","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.phrs.2015.03.009_bib1825","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase iii study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2015.03.009_bib1830","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3\u20135","author":"Block","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2015.03.009_bib1835","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1358\/dnp.2007.20.3.1092097","article-title":"The beneficial effects of statins in autoimmune disease therapy","volume":"20","author":"Marai","year":"2007","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.phrs.2015.03.009_bib1840","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1002\/art.22169","article-title":"Rhoa-mediated, tumor necrosis factor alpha-induced activation of nf-kappa b in rheumatoid synoviocytes \u2013 inhibitory effect of simvastatin","volume":"54","author":"Xu","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.phrs.2015.03.009_bib1845","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2215\/CJN.09810913","article-title":"Association of walking with survival and rrt among patients with ckd stages 3\u20135","volume":"9","author":"Chen","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.phrs.2015.03.009_bib1850","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.01340214","article-title":"Depressive affect and hospitalization risk in incident hemodialysis patients","volume":"9","author":"Lacson","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2015.03.009_bib1855","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2215\/CJN.08670813","article-title":"Associations between depressive symptoms and incident ESRD in a diabetic cohort","volume":"9","author":"Yu","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2015.03.009_bib1860","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.5114\/aoms.2013.39792","article-title":"Treatment of non-st-elevation myocardial infarction and st-elevation myocardial infarction in patients with chronic kidney disease","volume":"9","author":"Franczyk-Sk\u00f3ra","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2015.03.009_bib1865","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2174\/157016110793563861","article-title":"Current place of beta-blockers in the treatment of hypertension","volume":"8","author":"Bielecka-Dabrowa","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2015.03.009_bib1870","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1681\/ASN.2014040324","article-title":"B-blocker dialyzability and mortality in older patients receiving hemodialysis","volume":"26","author":"Weir","year":"2015","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T06:30:55Z","timestamp":1651645855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661815000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":187,"alternative-id":["S1043661815000481"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.03.009","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipids, blood pressure and kidney update 2014","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}